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Abstract. Theaflavin-3, 3'-digallate (TF3) is a black tea polyphenol produced from polymerization and oxidization of the
green tea ployphenols epicatechin gallate and (-)-epigallocatechin-3-gallate (EGCG) during fermentation of fresh tea leaves.
TF3 has been reported to have anticancer properties. However,
the effect of TF3 on tumor angiogenesis and the underlying
mechanisms are not clear. In the present study, TF3 was verified to inhibit tumor angiogenesis. Compared with EGCG,
TF3 was more potent. TF3 inhibited human ovarian carcinoma
OVCAR-3 cell-induced angiogenesis in human umbilical vein
endothelial cell model and in chick chorioallantoic membrane
model. TF3 reduced tumor angiogenesis by downregulating
HIF-1α and VEGF. One of the mechanisms was TF3 inactivated Akt/mTOR/p70S6K/4E-BP1 pathway and Akt/c-Myc
pathway. Besides, TF3 suppressed the cleavage of Notch-1,
subsequently decreased the expression of c-Myc, HIF-1α
and VEGF, and finally the impaired cancer cells induced
angiogenesis. Nevertheless, TF3 did not have any influence on
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the MAPK pathways. Taken together, these findings suggest
that TF3 might serve as a potential anti-angiogenic agent for
cancer treatment.
Introduction
Epithelial ovarian cancer is the most lethal gynecological
cancer (1). Cytoreductive surgery with chemotherapy is the
standard of care for ovarian cancer (2). However, 20-40%
of patients do not respond to first-line chemotherapy (3).
Furthermore, a large proportion of patients will have a relapse
of the disease within 5 years (1), especially those in advanced
stage. Unfortunately, recurrence is typically less responsive to
current chemotherapeutic strategies (1).
Angiogenesis plays an important role in the growth and
progression of solid tumors (4). Tumor angiogenesis is characterized by the formation of new irregular blood vessels from
a preexisting vascular network (5). Tumor vasculature usually
has poor blood flow and high vascular permeability, which
may lead to decreased efficiency of cytotoxic chemotherapy
and increased potential for metastasis (6). Angiogenesis can
be regulated by many signaling molecules and growth factors,
including vascular endothelial growth factor (VEGF). VEGF
is a crucial factor in modulating multiple vascular steps. VEGF
expression can be upregulated by hypoxia-inducible factor 1
(HIF-1). HIF-1 is a basic-loop helix PER-ARNT-SIM transcription factor consisting of two subunits, HIF-1α and HIF-1β.
Overexpression of HIF-1α has been demonstrated in >70% of
human cancers and metastases compared to adjacent normal
tissue (7). Stabilization and upregulation of HIF-1α promotes
the expression of VEGF by binding to HIF-responsive elements
in promoters. Therefore, anti-angiogenic agents targeting
HIF-1α and VEGF are highlighted for anticancer treatment.
Black tea is one of the most popular beverages worldwide.
Basic procedures of making black tea include withering,
rolling, fermentation, and drying. During the fermentation
process, green tea polyphenols are polymerized and oxidized
to form oligomeric flavanols, such as theaflavins, thearubigin
and other oligomers (8). Thus black tea has low tea catechin
content (9). Theaflavins account for 2-6% of the dry weight of
solids in brewed black tea (9). Theaflavin-3, 3'-digallate (TF3)
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(Fig. 1A) is one of the four main theaflavins in black tea, which
is produced by the oxidative dimerization of epicatechin
gallate (ECG) and (-)-epigallocatechin-3-gallate (EGCG).
TF3 is a potent anticancer agent. It showed inhibitory effects
on the growth of various human cancer cells (10). It induced
apoptosis and cell cycle arrest in cancer cells by generating
reactive oxygen species and/or modulating signaling pathways (8,11,12). Recently, theaflavins were observed to exhibit
anti-angiogenic activities. TF3 inhibited tube formation in
cocultured endothelial cells with fibroblasts (13). In human
prostate cancer-bearing athymic nude mice, theaflavins
significantly diminished the expression of VEGF in tumors
(14). Nevertheless, the mechanisms remain unclear.
In the present study, the antitumor-induced angiogenic
effect and mechanisms of TF3 were investigated. TF3
impaired human ovarian carcinoma OVCAR-3 cell-induced
angiogenesis. Part of the underlying mechanisms was TF3
targeted Akt/mTOR/p70S6K/4E-BP1 pathway, Akt/c-Myc
pathway and Notch-1/c-Myc pathway to regulating HIF-1α and
VEGF expression in OVCAR-3 cells. Our study suggests that
TF3 can be regarded as a candidate anti-angiogenic agent for
the adjunctive therapy of cancer.
Materials and methods
Cell cultures and reagents. Human ovarian carcinoma cell
line OVCAR-3, a kind gift from Dr Bing-Hua Jiang, Thomas
Jefferson University, was cultured in RPMI-1640 medium
(Sigma, St. Louis, MO, USA) incorporating 10% fetal bovine
serum (FBS) (Invitrogen, Grand Island, NY, USA). Human
umbilical vein endothelial cells (HUVECs), purchased from
American Type Culture Collection (ATCC, Manassas, VA,
USA), were maintained in F-12K medium (ATCC) supplemented with 10% FBS (Invitrogen) and Endothelial Cell
Growth Kit-VEGF (ATCC). Cells were grown in a humidified
incubator containing 5% CO2 at 37˚C.
Reagents: TF3 monomer (purity: 92.4%) was isolated
and purified using previously established method (15).
Wortmannin and N-[N-(3,5-difluorophenacetyl)-L-alanyl]S-phenylglycine t-butyl ester (DAPT) were purchased
from Sigma and Santa Cruz Biotechnology (Santa Cruz,
CA, USA), respectively. Antibodies against phospho-Akt
(Ser473) (p-Akt), Akt, phospho-p70S6 kinase (Thr421/Ser424)
(p-p70S6K), p70S6K, eukaryotic initiation factor 4E-binding
protein-1 (4E-BP1), HIF-1α, Notch-1, c-Jun N-terminal
kinases (JNK), p38 and phosphor-Forkhead Box O1 (Thr24)
(p-FoxO1) were purchased from Cell Signaling Technology,
Inc. (Danvers, MA, USA). Antibodies against phosphormammalian target of rapamycin (p-mTOR) (Ser2448), mTOR
were purchased from R&D Systems (Minneapolis, MN,
USA). Antibodies against phosphor-4E-BP1 (Ser65/Thr70)
(p-4E-BP1), c-Myc, phosphor-extracellular signal-regulated
kinases 1/2 (Thr202/Tyr204) (p-ERK1/2), ERK1/2 and
GAPDH were purchased from Santa Cruz Biotechnology Inc.
(Santa Cruz). Plasmids (myrAkt delta4-129, pcDNA3-Flag
mTOR wt, pWZL Neo Myr Flag RPS6KB1, pET14b PHAS-I,
HA-HIF1alpha-pcDNA3, 3XFlagNICD1, pMXs-hc-MYC,
ODD-Luciferase-pcDNA3, VEGF promoter, cMyc promoter
(TBE1/2-wt), and pCBFRE‑luc) were purchased from Addgene
(Cambridge, MA, USA).

Cell viability assay. OVCAR-3 cells were seeded into 96-well
plates at a density of 2x104 per well in medium with 10% FBS.
After overnight growth, cells were treated with different
concentrations of TF3 for 24 h. Cell viability was measured
using CellTiter 96® Aqueous One Solution Cell Proliferation
assay (Promega, Madison, WI, USA), according to the
manufacturer's instructions. Cell viability was expressed as a
percentage compared to control cells (vehicle treatment).
HUVEC tube formation assay. Growth factor-reduced
Matrigel (50 µl) (BD Biosciences, San Jose, CA, USA) was
added into each well of a 96-well plate and polymerized for
30 min at 37˚C. HUVECs (1.5x104/well) in 100 µl conditioned
medium (90 µl F12-K medium+10 µl cell culture supernatant
of vehicle or TF3-treated OVCAR-3 cells) were seeded into
each growth factor-reduced Matrigel-coated well, incubated at
37˚C in 5% CO2 for 6 h, and photographed under a microscope.
Tube length was quantified using the NIH ImageJ software
(NIH, Bethesda, MD, USA). Tube length was expressed as a
percentage compared to the control group.
Chick chorioallantoic membrane (CAM) assay. Specific
pathogen-free fertile chicken eggs (Charles River Laboratories,
North Franklin, CT, USA) were incubated at 37.5˚C and slowly
turned by an automatic egg turner (G.Q.F. Manufacturing
Co., Savannah, GA, USA). On the 8th day of development of
fertilized chicken eggs, a 1-cm diameter window was opened
in the shell of each egg to expose the CAM. On the 9th day,
106 OVCAR-3 cells in 20 µl FBS-free RPMI-1640 medium
were mixed with 80 µl Matrigel (BD Biosciences), supplemented with TF3 at a final concentration of 25 µmol/l (µM) or
equivalent vehicle, and implanted onto the CAM. After incubating for another 5 days, tumor implants and blood vessels
were photographed and counted for branching blood vessels.
Blood vessel density was normalized to the control group.
Enzyme linked immunosorbent assays. OVCAR-3 cells were
seeded into 96-well plates at a density of 2x104 per well, incubated overnight and treated with different concentrations of
TF3 for 24 h. Cell culture supernatants were collected. The
concentration of human VEGF protein was determined by
a human VEGF Duo-set ELISA kit (R&D) according to the
manufacturer's instructions.
Western blot analysis. OVCAR-3 cells were treated for 24 h
with various concentrations of TF3 in 60 mm dishes, and
then lysed in 100 µl mammalian protein extraction reagent
supplemented with Halt™ Protease and Phosphatase Inhibitor
Single-Use Cocktail (Life Technologies, Grand Island, NY,
USA). The concentration of protein was measured using a
BCA Protein assay kit (Thermo, Waltham, MA, USA). Equal
amounts of protein were prepared and separated by SDS-PAGE
and transferred onto the nitrocellulose membranes with a
Mini-Protean 3 system (Bio-Rad, Hercules, CA, USA). The
membrane was blocked with 5% non-fat milk in Tris-buffer
saline containing 0.1% Tween-20 for 1 h at room temperature
and incubated with indicated primary antibodies overnight at
4˚C followed by horseradish peroxidase-conjugated secondary
antibody for 2 h at 37˚C. Detection was performed by
SuperSignal West Dura Extended Duration Substrate (Life
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Figure 1. Theaflavin-3, 3'-digallate (TF3) inhibits OVCAR-3 cell-induced angiogenesis by targeting HIF-1α and VEGF. (A) Molecular structure of TF3.
(B) Viability of OVCAR-3 cells was decreased after TF3 treatment for 24 h. (C) OVCAR-3 cells-induced HUVEC tube formation was inhibited by TF3
treatment. (D) OVCAR-3 cell-induced blood vessel development in the CAM model was reduced by TF3 treatment. (E) The protein level of VEGF in TF3treated OVCAR-3 cell culture supernatant was reduced. (F) TF3 diminished the transcriptional activity of VEGF promoter, and, overexpression of HIF-1α
reversed it. The data are presented as the mean ± standard error of mean. *P<0.05 compared with control or between specific groups.

Technologies) and ChemiDoc™ MP System (Bio-Rad).
Protein bands were quantified with the NIH ImageJ software
(NIH), normalized by corresponding GAPDH for analysis.

Transient transfection and luciferase reporter assay.
OVCAR-3 cells were seeded in 96-well plates at a density
of 2x104 per well and transfected with plasmids (including
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Figure 2. Angiogenesis-related proteins are affected by TF3 treatment in OVCAR-3 cells. Western blot analysis revealed that TF3 decreased the protein level of
p-Akt, p-mTOR, p-p70S6K, p-4E-BP1, Notch-1 (NICD), c-Myc and HIF-1α in OVCAR-3 cells. TF3 had no impact on the protein level of p-ERK1/2, ERK1/2,
JNK, p38 and p-FoxO 1. GAPDH served as the loading control.

a targeted gene plasmid, a corresponding luciferase reporter
plasmid and β-galactosidase control vector) using jetPrimeTM
DNA and siRNA Transfection reagent (VWR International,
West Chester, PA, USA). Four hours later, medium was
replaced by FBS-free RPMI-1640 medium containing TF3
or equivalent vehicle. Cells were incubated for another 24 h.
Luciferase assays and β-galactosidase assay were performed
using One-Glo™ luciferase assay system and β-galactosidase
enzyme assay system (Promega), respectively. Luciferase
activity was expressed relative to β-galactosidase activity.
Statistical analysis. The data are expressed as mean ± standard
error of mean (SEM) from at least three independent experiments. The results were analyzed with SPSS Version 18.0 for
Windows (SPSS, Chicago, IL, USA) using one-way analysis of
variance (ANOVA) and post hoc test (2-sided Dunnett's test) to
test both overall differences and specific differences between
each treatment and control. P-values <0.05 were considered
statistically significant.
Results
TF3 reduces tumor-induced angiogenesis in vitro and in vivo
by downregulating VEGF and HIF-1α. To evaluate the cytotoxicity of TF3 on OVCAR-3 cells, CellTiter 96® Aqueous One
Solution Cell Proliferation assay was performed (Fig. 1B). TF3
treatment for 24 h dose-dependently inhibited the viability
of OVCAR-3 cells, ranging from 100 to 48.3%. The antiproliferative activity of TF3 is weak at low concentrations.

The viability of OVCAR-3 cells was >70% when treated with
concentrations of 15 µM and below of TF3.
Black tea extracts, which contains theaflavins, has been
reported to inhibit tumor angiogenesis. To assess whether TF3
repressed angiogenesis induced by OVCAR-3 cells, HUVEC
tube formation assay was carried out. HUVECs were cultured
in F12-K medium supplemented with cell culture supernatant
of vehicle or TF3-treated OVCAR-3 cells. Mature, interconnected capillary-like networks were observed in the control
group. However, the tube-like structures found in TF3-treated
groups were less organized and leaky. Tube length was
determined to quantify tube formation. The data showed TF3
interrupted OVCAR-3 cell-induced HUVEC tube formation in
a dose-dependent manner (Fig. 1C).
To examine the anti-angiogenic potential of TF3 in vivo,
CAM assay was conducted. Highly vascularized structure was
found in the control group. TF3 treatment markedly reduced
blood vessel density. These results confirmed that TF3 inhibited cancer cells induced angiogenesis in vivo (Fig. 1D).
VEGF is an important growth factor involved in tumor
vascular development and maintenance. We examined the
effect of TF3 on VEGF secretion using a VEGF ELISA kit.
The protein level of VEGF in TF3-treated OVCAR-3 cell
culture supernatant was much lower compared with that in the
control group. TF3 had an excellent activity on diminishing
the secretion of VEGF (Fig. 1E), indicating TF3 inhibited
tumor angiogenesis by targeting VEGF.
HIF-1α has a direct regulatory impact on the expression of
VEGF. Western blot analysis revealed that TF3 significantly
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Figure 3. Akt/mTOR/p70S6k/4E-BP1 pathway and Akt/c-Myc pathway are involved in TF3-induced inhibition of HIF-1α and VEGF. (A) Western blot analysis
showed that 100 nM wortmannin, 10 µM TF3 and 100 nM wortmannin+10 µM TF3 decreased the phosphorylation of Akt, mTOR, p70S6K and 4E-BP1, and
expression of c-Myc and HIF-1α. TF3+wortmannin exhibited the strongest effect among them. GAPDH served as the loading control. (B) Luciferase reporter
assay and (C) VEGF ELISA showed 100 nM wortmannin, 10 µM TF3 and 100 nM wortmannin+10 µM TF3 suppressed the transcriptional activity of VEGF
promoter and VEGF secretion, respectively. TF3+wortmannin elicited strongest effect among them. (D) Overexpression of active Akt attenuated the 15 µM
TF3-induced decrease of phosphorylation of Akt, mTOR, p70S6K and 4E-BP1, and expression of c-Myc and HIF-1α.

decreased the protein level of HIF-1α in OVCAR-3 cells
(Fig. 2). The data of luciferase reporter assay implied TF3
strongly eliminated the transcriptional activity of VEGF
promoter. However, this inhibitory effect was abrogated by
overexpression of HIF-1α (Fig. 1F). It hinted TF3 downregulated VEGF by repressing HIF-1α expression in OVCAR-3
cells.
TF3 inhibits HIF-1α and VEGF via Akt/mTOR/p70S6K/4EBP1 pathway. Previous studies demonstrated that PI3K/Akt
signaling was required for VEGF expression through HIF-1 in
response to growth factor stimulation and oncogene activation
(16). mTOR/p70S6K/RPS6/4E-BP1 signaling pathway also
played an important role in suppressing HIF-1α and VEGF
expression (17). To explore whether TF3 decreased HIF-1α and
VEGF expression via Akt pathway, the protein levels of PTEN,

p-Akt, Akt, p-mTOR, mTOR, p-p70S6K, p70S6K, p-4E-BP1
and 4E-BP1 were detected by western blot analysis. As shown
in Fig. 2, TF3 significantly lowered the protein levels of p-Akt,
p-mTOR, p-p70S6K and p-4E-BP1. Whereas, the expression
of PTEN, a negative regulator of the Akt pathway, was not
affected by TF3 treatment. The result indicated that TF3 inactivated Akt pathway through inhibiting the phosphorylation of
Akt, mTOR, p70S6K and 4E-BP1 in OVCAR-3 cells.
When treated with TF3 and wortmannin, a selective Akt
pathway inhibitor, an additive inhibitory effect on Akt pathway
was observed in OVCAR-3 cells. The protein levels of p-Akt,
p-mTOR, p-p70S6K, p-4E-BP1, HIF-1α and VEGF in TF3
and wortmannin co-treated cells were much more reduced
compared with that in TF3 or wortmannin alone treated cells
(Fig. 3A and C). Consistent with this, the result of luciferase
reporter assay validated the transcriptional activity of VEGF
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Figure 3. Continued. Overexpression of Akt, mTOR, p70S6K or 4E-BP1 attenuated TF3-induced inhibition of transcriptional activity of VEGF promoter (E)
and HIF-1α promoter (F). (G) Overexpression of active Akt reversed the 15 µM TF3-induced reduction of VEGF secretion. The data are presented as the mean
± standard error of mean. *P<0.05 compared with control or between specific groups.
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Figure 4. Notch-1/c-Myc pathway is related to TF3-induced inhibition of HIF-1α and VEGF. (A) Western blot analysis showed that 10 µM TF3, 75 µM
DAPT and 10 µM TF3+75 µM DAPT decreased the expression of NICD, c-Myc and HIF-1α. The dose of 10 µM TF3+75 µM DAPT exhibited the strongest
effect. GAPDH served as the loading control. (B) Luciferase reporter assay and (C) VEGF ELISA showed 10 µM TF3, 75 µM DAPT and 10 µM TF3+75 µM
DAPT suppressed the transcriptional activity of VEGF promoter and VEGF secretion, respectively. (D) Overexpression of NICD attenuated 15 µM TF3induced decrease of NICD, c-Myc and HIF-1α. (E) Overexpression of NICD or c-Myc attenuated TF3-induced inhibition of transcriptional activity of VEGF
promoter and HIF-1α promoter. (F) Overexpression of NICD or active Akt attenuated TF3-induced inhibition of transcriptional activity of c-Myc promoter.
(G) Overexpression of NICD reversed the 15 µM TF3-induced reduction of VEGF secretion. The data are presented as the mean ± standard error of mean.
*
P<0.05 compared with control or between specific groups.
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Figure 5. EGCG decreases VEGF secretion of OVCAR-3 cells. (A) Chemical structure of epicatechin gallate. (B) Chemical structure of EGCG. (C) Viability
and (D) VEGF secretion of EGCG-treated OVCAR-3 cells. All data are presented as the mean ± standard error of mean. *P<0.05 compared with the control
group.

promoter was lower than that in TF3 or wortmannin alone
treated cells (Fig. 3B). On the contrary, transfected OCVAR-3
cells with a plasmid expressing constitutively active Akt made
the cells less responsive to TF3 treatment. TF3-mediated
decrease in the protein levels of p-Akt, p-mTOR, p-p70S6K,
p-4E-BP1, HIF-1α and VEGF was partially attenuated in
Akt-overexpressing OVCAR-3 cells (Fig. 3D and G). Besides,
transfected cells with plasmid expressing Akt, mTOR, p70S6K
or 4E-BP1 reversed TF3-induced transcription inhibition of
VEGF promoter and HIF-1α promoter (Fig. 3E and F). These
data provided evidence that TF3 reduced HIF-1α and VEGF
via Akt/mTOR/p70S6K/4E-BP1 pathway in OVCAR-3 cells.
TF3 suppresses HIF-1α and VEGF via Akt/c-myc and
Notch‑1/c-myc pathway. c-Myc is a major human oncogene
which exerts many biological functions. It has been elucidated
that c-Myc enhances cancer cell-mediated angiogenesis
through the regulation of HIF-1α (18). c-Myc expression
can be regulated in an Akt-dependent manner at the level of
transcription (19). c-Myc expression also can be affected by
Notch-1. Notch-1 upregulates c-Myc transcription by directly
binding to its promoter (20). To investigate whether Akt/c-Myc
and Notch‑1/c-Myc participated in tumor angiogenesis and
the influence of TF3 on these pathways, western blot analysis
and luciferase reporter assay were carried out. According to
the results, TF3 significantly suppressed the expression of
c-Myc, HIF-1α and VEGF, the cleavage of Notch-1, and the
phosphorylation of Akt (Figs. 1E and 2). TF3 and wortmannin
co-treatment enhanced the effect of TF3 on decreasing the
protein levels of c-Myc, HIF-1α and VEGF (Fig. 3A and C),

while overexpression of active Akt rescued it (Fig. 3D and G).
Similarly, exposure to the combination of TF3 and DAPT,
a Notch inhibitor, caused a stronger repression of c-Myc
and HIF-1α than DAPT or TF3 alone (Fig. 4A). Whereas,
overexpression of Notch-1 intracellular domain (NICD) had
an adverse effect on the TF3-triggered inhibition of c-Myc,
HIF-1α and VEGF expression (Fig. 4D and G). Luciferase
reporter assay confirmed that wortmannin, DAPT and TF3
declined the transcriptional activity of VEGF promoter
(Figs. 3B and 4B). On the contrary, overexpression of active
Akt or NICD abrogated TF3-induced transcription inhibition
of c-Myc promoter, HIF-1α promoter and VEGF promoter
(Figs. 3E and F, and 4E and F). Transfected cells with plasmid
expressing c-Myc eliminated TF3-induced transcription
inhibition of HIF-1α and VEGF (Fig. 4E). Taken together,
Akt/c-Myc/HIF-1α /VEGF pathway and Notch-1/c-Myc/
HIF-1α/VEGF pathway are involved in the antitumor angiogenic mechanisms of TF3.
TF3 does not affect HIF-1α and VEGF via the MAPK
pathways. MAPK pathways play essential roles in cell proliferation and differentiation. Activation of MAPK signaling
pathways has been reported to participate in tumorigenesis,
metastasis, and angiogenesis of multiple human malignancies (21). To investigate whether TF3 had an influence on
MAPK pathways, western blot assay was carried out. In this
study, TF3 showed no sign of affecting the protein levels
of p-ERK1/2, ERK1/2, JNK, p38 and p-FoxO1 (Fig. 5),
suggesting MAPK pathways were not relevant to the antitumor angiogenic activity of TF3.
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Figure 6. Proposed mechanism of inhibition of tumor angiogenesis via Akt and Notch-1 pathways.

Discussion
Ovarian cancer is one of the most common cancers in women.
Due to the fact that current chemotherapies do not work on a
proportion of patients and may cause severe side effect, it is
critical to identify alternative strategies. Some nutrients were
found to have anticancer activities with little side effect. A
previous study presented that black tea consumption was associated with a linear decline in ovarian cancer risk (22). TF3 is
produced in black tea manufacturing process. It has multiple
biological activities, including the anti-oxidant, anti-bacterial,
anti-obese, and anticancer effects. TF3 inhibits proliferation
and/or induce apoptosis of various cancer cells (11,12). In this
study, we tested the cytotoxicity of TF3 on OVCAR-3 cells
and found TF3 inhibited cell proliferation, especially at high
concentrations. This is consistent with the former research that
theaflavins exhibited anti-proliferative and apoptotic activity
in human teratocarcinoma of ovarian origin (23). Although
previous studies and the current study proved TF3 exerted an
anti-proliferative effect of cancer cells, the working concentrations were much higher than the attainable concentrations of
TF3 in plasma and tissues (24).
Previous studies showed that some food-derived natural
compounds elicited growth inhibitory activity at higher
concentrations while anti-angiogenic activity at relatively
lower concentrations (25,26). Tumor angiogenesis is related
with poor prognosis in ovarian carcinoma (27). Cancer cells
can secrete pro-angiogenic factors, including VEGF and basic
fibroblast growth factor, to stimulate normal endothelial cell
growth through paracrine mechanisms (28). VEGF regulates
the key steps of angiogenic process, particularly endothelial
cell proliferation, survival, permeability, and migration (29).
TF3 has been demonstrated to inhibit gene expression of VEGF
in A549 lung cancer cells (30). However, the impact of TF3 on
ovarian cancer-induced angiogenesis has not been reported yet.
To explore whether TF3 hampered tumor induced angiogenesis,
we tested the anti-angiogenic activity of TF3 in the HUVEC
model and CAM model, and the VEGF protein content in the
cell culture supernatant of TF3-treated OVCAR-3 cells. In
this study, TF3 was verified to block OVCAR-3 cell-triggered
HUVEC tube formation and blood vessel development in
the CAM model. TF3 started to inhibit HUVEC tube formation at 5 µM. About half of OVCAR-3 cell-induced HUVEC
tube formation was blocked after 15 µM TF3 treatment. The
result of VEGF ELISA was in accordance with that of tube
formation assay. TF3 strongly reduced the VEGF secretion of
OVCAR-3 cells. Treatment with 5 µM TF3 caused an ~50%
decline of VEGF secretion. The data implied that TF3 might
exert its antitumor angiogenic function by downregulating

VEGF. It also provided evidence supporting a multifunction
of TF3 on OVCAR-3 cells between different concentrations.
In the present study, we also measured the effect of EGCG,
a precursor of TF3, on VEGF secretion of OVCAR-3 cells.
EGCG was regarded as one of the most potent bioactives in
green tea and has been proven to inhibit tumor angiogenesis
(31). Compared with EGCG, the working concentration of TF3
was much lower (Fig. 5D). One of the possible reasons might
be that TF3 was more stable than EGCG in aqueous system
(pH 7.4) (32). Structural differences might also be responsible
for this (Figs. 1A and 5B). The activity of tea polyphenols is
related with the number and position of hydroxyl groups in
molecules (33). TF3 is produced by the oxidative dimerization
of ECG and EGCG. Therefore, TF3 contains more hydroxyl
groups than ECG or EGCG alone.
HIF-1α is a subunit of the heterodimeric transcription
factor HIF-1, which regulates the transcription of >60 genes,
including VEGF. Dysregulation and overexpression of HIF-1α
are heavily implicated in cancer biology, specifically in areas
of vascularization and angiogenesis. Constitutively elevated
levels of HIF-1α protein were detected under normal conditions in OVCAR-3 cells (16). We observed TF3 remarkably
decreased the expression of HIF-1α in OVCAR-3 cells.
Luciferase reporter assay suggested TF3 inhibited VEGF by
suppressing HIF-1α. EGCG has been reported to suppress
breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and expression of VEGF (34). Similar functions
of EGCG were also found in human cervical carcinoma and
hepatoma cells (35). It suggested that HIF-1α/VEGF might be
key therapeutic targets for tea polyphenols.
Multiple signaling pathways are involved in the regulation
of HIF-1α/VEGF. One of them is the Akt signaling pathway.
Akt signaling pathway has been considered to participate in
angiogenesis in the neoplastic and non-neoplastic process
(36). Growth factors, cytokines, and other signaling molecules
stimulate HIF-1 protein synthesis via activation of Akt
pathway (16). The activation of Akt pathway starts from the
phosphorylation of Akt. Then, mTOR can be phosphorylated and activated by Akt. Subsequently, activated mTOR
regulates the phosphorylation and activation of p70S6K
and 4E-BP1, two known downstream targets of mTOR
(37). Active p70S6K and 4E-BP1 enhance the translation of
mRNAs that bear a 5' terminal oligopyrimidine tract, which
encodes proteins related with the translational apparatus like
ribosomal proteins, elongation factors and the poly A-binding
protein (38). In the present study, we proved TF3 markedly
decreased the phosphorylation of Akt, mTOR, p70S6K, and
4E-BP1, reduced the expression of HIF-1α and VEGF. This
effect was potentiated by the PI3K/Akt inhibitor wortmannin
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and impaired by overexpression of active Akt. This is the
first report that Akt/mTOR/p70S6K/4E-BP1/HIF-1α /VEGF
pathway was involved in the anti-angiogenic effect of TF3.
Recently, some natural compounds have been proven to inhibit
HIF-1α and VEGF expression by targeting Akt signaling
pathway. Quercetin, a flavonol found in many fruits and
vegetables, inhibited angiogenesis mediated human prostate
tumor growth by targeting VEGFR-2 regulated Akt/mTOR/
p70S6K signaling pathways (39). Silibinin, a natural flavonoid
extracted from the milk thistle seeds, suppressed HIF-1α
and mTOR/p70S6K/4E-BP1 signaling pathway in human
cervical and hepatoma cancer cells (17). Tanshinone IIA, a
derivative of phenanthrene-quinone from the dried root of
Salvia miltiorrhiza, regulated breast cancer growth and tumor
angiogenesis via mTOR/p70S6K/RPS6/4E-BP1-mediated
repression of HIF-1α and VEGF expression (37). Our study
was in agreement with the previous studies and suggested that
Akt/mTOR/p70S6K/4E‑BP1/HIF-1α/VEGF pathway was an
important target for plant-derived nutrients to inhibit tumor
angiogenesis.
c-Myc is a transcription factor essential for vasculogenesis
and angiogenesis during development and tumor progression
(40). Targeting c-Myc/HIF-1α pathway inhibits cancer growth
and angiogenesis (41).
Akt pathway has an influence on c-Myc (19). LY294002,
a PI3K/Akt inhibitor, reduced c-Myc expression and regulated
the degradation of c-Myc via affecting the phosphorylation status of Thr58 (19). In this study, western blot analysis
revealed that c-Myc expression and phosphorylation of Akt
was greatly inhibited by TF3. Hence, we hypothesized that
Akt/c-Myc/HIF-1α pathway might be related to the antitumor angiogenic effect of TF3. To confirm this hypothesis,
western blot and luciferase reporter assay were performed.
Both TF3 and wortmannin inhibited the activation of Akt,
expression of c-Myc, HIF-1α and VEGF. TF3 and wortmannin
combination led to a more effective suppression. Conversely,
transfected cells with plasmid expressing active Akt enhanced
TF3-resistance of OVCAR-3 cells. These results indicated that
TF3 inhibited HIF-1α and VEGF via Akt/c-Myc pathway.
Akt/c-Myc pathway has been discovered to have an impact
on cellular metabolism, cell proliferation and the cell cycle.
Akt or c-Myc alone has been proven to regulate angiogenesis
via HIF-1α/VEGF pathway. In this study, Akt and c-Myc was
demonstrated to be relevant in stimulating tumor angiogenesis.
Akt regulated the pro-angiogenic effect of c-Myc through
modulating the expression of c-Myc. Thus, we discovered
a novel target pathway responsible for the anti-angiogenic
activity of TF3 in OVCAR-3 cells.
Notch-1 is important upstream of c-Myc. It modulates
the expression of c-Myc by directly binding to its promoter.
Notch-1 is a type I transmembrane receptor. When binding
to its ligands, metalloproteinase-mediated and γ-secretasemediated cleavage is induced. Subsequently, NICD is released
from plasma membrane, translocated into the nucleus, and
binds CBF-1/suppressor of hairless/Lag-1, mastermind-like-1,
and p300/CBP, to form a transcriptional coactivator (42).
Notch-1 is a regulator of tumor angiogenesis (43). Previous
studies showed overexpression of Notch-1 promoted cell
growth and tumor angiogenesis in myeloma (44). Whereas,
Notch-1 antibody presents an adverse effect on tumor growth

and angiogenesis (45). β-elemene, a sesquiterpene found in a
variety of plants, has been demonstrated to attenuate angiogenesis capacity of CD44+ gastric cancer stem-like cells by
interfering with the expression of Notch-1 (46). Notch-1
signaling is active in ovarian cancer (47). In the present study,
we observed TF3 inhibited the cleavage of Notch-1. To verify
whether there was a link between Notch‑1/c-Myc pathway and
HIF-1α /VEGF pathway, DAPT, a γ-secretase inhibitor was
used. According to the results, DAPT lowered the expression
of NICD, c-Myc, HIF-1α and VEGF. It hinted that HIF-1α
and VEGF were regulated by Notch-1/c-Myc pathway in
OVCAR-3 cells. Further experiments revealed that TF3
promoted the repressive effect of DAPT on Notch-1/c-Myc
pathway. On the contrary, overexpression of NICD hampered
TF3-trigged inhibition of these proteins. Based on the above
results, we concluded that TF3 downregulated HIF-1α and
VEGF partially by suppressing Notch-1/c-Myc pathway. The
protein level of NICD in TF3 and/or DAPT treated cells was
control group>TF3 group>DAPT group>TF3+DAPT group,
while the protein levels of c-Myc and HIF-1α were control
group>DAPT group>TF3 group>TF3+DAPT group. This
inconsistence could be explained by TF3 suppressing c-Myc/
HIF-1α pathway not only via Notch-1, but also other targets
(for example, Akt pathway). Besides, the combination of TF3
and DAPT failed to cause an additive effect on decreasing
VEGF secretion, implying Notch-1/c-Myc pathway might only
play a subordinate role in the anti-angiogenic function of TF3.
MAPK pathways regulate many cellular activities,
including angiogenesis. MAPKs are activated by the dual
phosphorylation of neighboring threonine and tyrosine residues in response to various extracellular stimuli (48). ERK,
JNK and p38 are three major groups of MAPKs. ERKs are
often activated by growth signals, while JNK and p38 are
often initiated by stress-responsive signaling (48). FoxO1 is
a forkhead transcription factor which specifically regulates
a nonredundant, but overlapping set of angiogenesis- and
vascular remodeling-related genes (49). FoxO1 contains
15 consensus phosphorylation sites for the MAPK family. It
has been demonstrated that ERK and p38 directly regulated
the transcriptional activity of FoxO1 via phosphorylation (50).
Similarly, JNK-dependent phosphorylation of FoxO proteins
results in nuclear accumulation and enhanced transcriptional
activity (51). In the former studies, EGCG inhibited tumor
angiogenesis through inactivating ERK1/2 in human colon
carcinoma cells (52) and human pancreatic tumors (53). EGCG
increased the activity of p38, but not ERK 1/2 in OVCAR-3
cells (54). In HUVECs, inhibition of PI3K/AKT and MEK/
ERK pathways enhanced the anti-angiogenic effects of
EGCG through activation of FoxO transcription factors (48).
However, we did not observe any effect of TF3 on ERK1/2,
JNK or p38 in this case. This result implicated that although
TF3 and EGCG shared some anti-angiogenic targets, they had
their specific targets. This might be related to their molecular
structures. TF3 possesses a benzotropolone skeleton that is
formed from co-oxidation of EGCG and ECG, one with a
vic-trihydroxy moiety and the other with an ortho-dihydroxy
structure (9). The benzotropolone moiety has been proven to
be important in the antioxidant activity (55), anti-inflammatory activity (56), anti-peptide transport activity and activating
AMP-activated protein kinase (57). Thus, we speculated that
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benzotropolone moiety might also be vital for its anticancer
activity. Quantitative structure-activity relationship analysis
should be carried out to investigate this assumption.
In conclusion, this study presented that TF3 had the ability
to inhibit ovarian cancer cell-induced angiogenesis in vitro and
in vivo. TF3 exerted this effect through suppression of HIF-1α
and VEGF. One of the mechanisms is that TF3 inhibited Akt/
mTOR/p70S6K/4E-BP1 pathway. Other mechanisms included
TF3-mediated inactivation of Akt/c-Myc and Notch‑1/c-Myc
pathways. MAPK pathways were not involved. This study
provides novel perspectives and potential targets for the
anticancer activity of TF3 (Fig. 6). Further studies in animal
models and human trials are needed to evaluate the antitumor
angiogenic activity of TF3.
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